Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
2
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
3
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
4
Luciano Costa, MD, Discusses the Changing Treatment Paradigm in Myeloma
5